Pfizer touts bladder cancer results as first advancement for some patients...
Pfizer said its experimental anti-PD-1 drug bested the current standard of care in a type of bladder cancer where progress has been limited. Its therapy, called sasanlimab, significantly prolonged...
View ArticleLawmakers ask administration to tighten China trial rules
Members of Congress working on anti-China legislation have asked the US Commerce Department to harden its policies around who can run clinical trials at sites operated by the People’s Liberation Army....
View ArticleFDA adcomm votes to support Seikagaku's herniated disc injection
Despite some safety concerns, an FDA advisory committee on Friday voted 8 to 4 in favor of Japan-based Seikagaku's condoliase injection for the treatment of radicular leg pain associated with lumbar...
View ArticleObesity drug startup Metsera files for IPO
Metsera has filed to go public less than a year after its launch, capitalizing on the fervent investor interest — and intense competition — for all things obesity. The startup's sprint toward an IPO...
View ArticleBiogen offers to buy Sage Therapeutics for $469M
Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long slide...
View ArticleDNA edit leads to apparent cure in infant; CDER director to step down; More...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticlePharma is losing the AI talent war against startups: Analysis
Last month, NeurIPS, the biggest AI research conference, turned Vancouver’s convention center into a battleground for wooing AI talent. The recruiting trenches of the expo floor featured hundreds of...
View ArticleTune Therapeutics raises $175M Series B for epigenetic editing
In genetic medicine, a drumbeat of layoffs and pipeline cuts has replaced the excitement of just a few years ago, when fresh financing rounds were coming almost as often as new editing technologies and...
View ArticleThe embryo editing debate is back, revived by Nature article
Six years ago, Chinese researcher He Jiankui stunned the world by announcing the birth of the first two babies whose genes were edited as embryos. An ethical red line was crossed and condemnation from...
View ArticleJ&J looks at potential bid for Intra-Cellular — report
Johnson & Johnson is considering an acquisition of CNS drugmaker Intra-Cellular Therapies, according to anonymous sources cited in a Bloomberg News report on Sunday. If J&J follows through with...
View ArticleLantheus to buy Life Molecular Imaging for $350M, netting Alzheimer's diagnostic
Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its commercial Alzheimer’s diagnostics business. In addition to the $350...
View ArticleGSK acquires IDRx and its rare cancer drug for $1B upfront
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held biotech IDRx for $1 billion upfront, bringing a rare cancer treatment into the...
View ArticleBayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to...
Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test for regenerative medicine in neurologic conditions. The therapy, known as...
View ArticleRegor’s obesity pill posts muted weight loss in Phase 2a, enters new trial
The weight loss with Regor Therapeutics’ obesity pill does not look quite as strong as competing products — and the biotech’s interest in finding a partner for the asset might be harder to gratify....
View ArticleGilead taps into STAT6 space via $250M deal with Leo Pharma
Gilead has inked a deal to license Leo Pharma’s portfolio of oral STAT6 candidates for inflammatory diseases, less than a month after Johnson & Johnson dipped its toes into the same arena. Gilead...
View Article#JPM25: Day 1 at the JP Morgan Healthcare Conference
It’s day 1 at JP Morgan Healthcare Conference, and the dealmaking is already underway with three early announcements: GSK will acquire the privately-held biotech IDRx for $1 billion upfront; Lilly is...
View ArticleJ&J to buy Intra-Cellular for $14.6B in latest neuroscience bet
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion in the biggest biotech M&A transaction since 2023. J&J is buying the Bedminster, NJ-based biotech for $132.00 per...
View ArticleAstraZeneca, CRISPR tools supplier Synthego ink gene editing enzyme licensing...
Genome engineering business Synthego will have access to AstraZeneca’s CRISPR gene editing enzyme in its second licensing agreement in the past year. Synthego plans on combining the enzyme, branded as...
View ArticleLilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about half a year after its $150 million Series C. The deal is worth a total ...
View ArticleAragen gets $100M to expand manufacturing footprint
Indian CDMO Aragen Life Sciences has secured a $100 million investment from Singapore-headquartered private equity firm Quadria Capital. Aragen will use the investment to expand its facilities to meet...
View Article